课题基金 / 基金详情

Understanding T cell immunity in anti-NMDAR encephalitis: Developing therapeutic tools for neurological autoimmunity.

Understanding T cell immunity in anti-NMDAR encephalitis: Developing therapeutic tools for neurological autoimmunity.
了解抗 NMDAR 脑炎中的 T 细胞免疫:开发神经性自身免疫的治疗工具。
批准号:
MR/T001313/1
负责人:
Rachel Brown
金额:
$33.27万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
在英国,每年有6000人患上脑炎(大脑炎症)。它通常会导致严重的残疾,包括癫痫发作,记忆问题,丧失独立性和失业,所有这些都会影响患者的家庭和护理人员。虽然许多病例是由感染引起的,但大量病例是由于异常免疫反应而发生的,其中免疫系统的细胞产生抗体,这些抗体攻击健康脑细胞表面的特定蛋白质。目前,虽然我们对免疫介导的脑炎有一些可用的治疗方法,但患者往往对治疗有抵抗力,反应不佳,需要在专科病房或重症监护室住院数月。我们迫切需要了解免疫介导的脑炎是如何以及为什么发生的,并确定新的治疗形式,以改善患者的康复和预后。目前还不知道是什么触发了导致脑炎的自身抗体的产生,但最近的证据表明,一种特定类型的免疫细胞(T细胞)在其产生中起着重要作用。此外,最近观察到,一些新的癌症治疗方法称为“检查点抑制剂”或更一般地称为“癌症免疫疗法”,其通过影响T细胞功能起作用,可引起免疫介导的脑炎和其他免疫介导的神经系统并发症。这些检查点抑制剂使正常的T细胞更积极地攻击癌细胞,但不幸的是,作为副作用,不受调节的T细胞会引起自身免疫,并损害健康的身体细胞,包括大脑中的细胞。拟议的项目有两个广泛的目标:(i)检测免疫介导的脑炎患者和检查点抑制剂治疗后神经系统并发症患者的T细胞反应功能;和(ii)使用现有技术的基因工程通过产生调节性免疫细胞(TMF)来开发靶向免疫抑制疗法,它可以在大脑中被激活以抑制炎症,而不管炎症的原因是什么。第一个目的是检测健康志愿者和患者的T细胞数量和功能,并研究是否更容易在发生脑炎和NMDAR自身抗体的患者中触发对特定脑蛋白(NMDAR肽)的不必要的T细胞应答。第二个目的是探索基因工程T细胞在免疫介导的脑炎治疗中的应用。虽然一些T细胞具有“攻击”功能,例如那些引起疾病的T细胞,但其他T细胞(调节性T细胞或T细胞)是免疫调节剂,可以抑制炎症。我们将使用最先进的基因工程来产生T细胞,它可以在进入大脑时被激活,并关闭异常炎症。设计一种个性化的、精确靶向的脑炎细胞疗法,不仅可以改变我们对脑炎的治疗方式,还可以改变我们对多发性硬化症等一系列其他脑部炎症性疾病的治疗方式。在过去的15年里,伦敦大学学院一直处于T细胞工程的前沿,现在拥有欧洲最大的基因工程免疫细胞临床转化管道。最近,基因工程T细胞已被引入作为儿童白血病的许可治疗。在大脑中,他们也在胶质母细胞瘤(一种脑瘤)患者中进行试验。我们的目标是在实验室完成这些细胞的临床前测试。如果成功,这将为未来3-5年的I期临床试验铺平道路。
英文摘要
Encephalitis (inflammation of the brain) affects 6000 people in the UK annually. It commonly causes significant disability, including seizures, memory problems, loss of independence and unemployment all of which affect families and carers of patients. While many cases are caused by infection, a large number occur as a result of abnormal immune responses, where cells of the immune system produce antibodies, which attack specific proteins on the surface of healthy brain cells. Currently, while we have some available treatments for immune-mediated encephalitis, often patients are resistant to treatment, respond poorly and need to remain in hospital for several months either on a specialist ward or the intensive care unit. There is a pressing need to understand how and why immune-mediated encephalitis occurs, and to identify new forms of treatment to improve recovery and outcomes for our patients. It is not known what triggers the generation of autoantibodies that cause encephalitis, but recent evidence has suggested an important role for a specific type of immune cell (T cells) in their generation. In addition, it has recently been observed that some new cancer treatments called 'checkpoint inhibitors' or more generally, 'cancer immunotherapy', which work by affecting T cell function, can cause immune-mediated encephalitis and other immune-mediated neurological complications. These checkpoint inhibitors make normal T cells attack cancer cells more aggressively, but unfortunately, as a side effect, unregulated T cells can cause autoimmunity and also damage healthy body cells including cells in the brain. The proposed project has 2 broad aims: (i) to characterise the function of T cell responses in patients with immune mediated encephalitis and with neurological complications after checkpoint inhibitor therapy; and (ii) to use state of the art genetic engineering to develop targeted immune suppressive therapies by generating regulatory immune cells (Tregs), which can be activated within the brain to suppress inflammation regardless of it's cause. For the first aim we will examine the number and function of T cells in healthy volunteers and in patients and investigate whether it is easier to trigger unwanted T cell responses to specific brain proteins (NMDAR peptides) in patients who develop encephalitis and NMDAR autoantibodies.For the second aim we will explore the use of gene-engineered T cells in the treatment of immune-mediated encephalitis. While some T cells have an 'attack' function, such as those causing disease, others (Regulatory T cells, or Tregs) are immune regulators and can suppress inflammation. We will use state-of-the-art genetic engineering to generate T regs which can become activated on entry into the brain, and switch off abnormal inflammation. Designing a personalised, precision-targeted cellular therapy for encephalitis, could transform the way we think about treating not just encephalitis, but a range of other inflammatory diseases of the brain, such as multiple sclerosis.Over the last 15 years, University College London has been at the forefront of T cell engineering and now has the largest clinical translation pipeline of genetically engineered immune cells in Europe. Recently gene-engineered T cells have been introduced as a licensed treatment for childhood leukaemias. In the brain, they are also being trialled in patients with glioblastoma, a type of brain tumour. We aim to complete pre-clinical testing of these cells in the laboratory. If successful this could pave the way for a phase I clinical trials in the next 3-5 years.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
122 Neurological manifestations of haemophagocytic lymphohistiocytosis
122 噬血细胞性淋巴组织细胞增多症的神经系统表现
DOI: 10.1136/jnnp-2022-abn.447
发表时间: 2022
期刊: Journal of Neurology, Neurosurgery & Psychiatry
影响因子: --
作者: [Brown R]
通讯作者: Brown R
DOI: 10.1016/j.eclinm.2021.101070
发表时间: 2021-09
期刊: EClinicalMedicine
影响因子: 15.1
作者: [Benjamin LA, Paterson RW, Moll R, Pericleous C, Brown R, Mehta PR, Athauda D, Ziff OJ, Heaney J, Checkley AM, Houlihan CF, Chou M, Heslegrave AJ, Chandratheva A, Michael BD, Blennow K, Vivekanandam V, Foulkes A, Mummery CJ, Lunn MP, Keddie S, Spyer MJ, Mckinnon T, Hart M, Carletti F, Jäger HR, Manji H, Zandi MS, Werring DJ, Nastouli E, Simister R, Solomon T, Zetterberg H, Schott JM, Cohen H, Efthymiou M, UCLH Queen Square COVID-19 Biomarker Study group]
通讯作者: UCLH Queen Square COVID-19 Biomarker Study group
The queen square encephalitis multidisciplinary meeting (infection and autoimmune): Pre and post COVID-19 experience (2018-2021)
皇后广场脑炎多学科会议(感染和自身免疫):COVID-19 前后的经验(2018-2021)
DOI: 10.1016/j.jns.2021.117801
发表时间: 2021
期刊: Journal of the Neurological Sciences
影响因子: 4.4
作者: [Brown R]
通讯作者: Brown R
068 Immune checkpoint inhibitors: the neurologist's role
068 免疫检查点抑制剂:神经科医生的作用
DOI: 10.1136/jnnp-2022-abn.105
发表时间: 2022
期刊: Journal of Neurology, Neurosurgery & Psychiatry
影响因子: --
作者: [Brown R]
通讯作者: Brown R
共 7 条
    国内基金
    海外基金
    全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
    • 批准号:
      QN25H220002
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      顾媛
    • 依托单位:
    T-cell Receptor信号通路调控基因的表达机制分子解析
    • 批准号:
      32570839
    • 项目类别:
      面上项目
    • 资助金额:
      50.00万元
    • 批准年份:
      2025
    • 负责人:
      范高峰
    • 依托单位:
    染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      15.0万元
    • 批准年份:
      2024
    • 负责人:
      王锐智
    • 依托单位:
    GMFG/F-actin/cell adhesion 轴驱动 EHT 在造 血干细胞生成中的作用及机制研究
    • 批准号:
      TGY24H080011
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      李鸿鹄
    • 依托单位: